Revisão sistemática de estudos comparando ximelagatrano versus varfarina para profilaxia do tromboembolismo venoso em cirurgia ortopédica
systematic review of randomized controlled trials
Palavras-chave:
Trombose venosa, Embolia pulmonar, Ortopedia, Prevenção primária, MetanáliseResumo
Revisão sistemática de estudos comparando ximelagatrano versus varfarina para profilaxia do trombo- embolismo venoso em cirurgia ortopédica INTRODUÇÃO: O ximelagatrano foi recentemente estudada para profilaxia do tromboembolismo venoso (TEV). OBJETIVO: Avaliar se o ximelagatrano comparado com a varfarina melhora a profilaxia do TEV em pacientes submetidos à cirurgia ortopédica do joelho. FONTE DE DADOS: Estudos randomizados identificados por pesquisa eletrônica na literatura médica, até 2006, cujos dados foram compilados no programa Review Manager, versão 4.2.5. RESULTADOS: Foram incluídos três estudos randomizados bem conduzidos envolvendo 4.914 participantes. Foram definidos dois sub-grupos com dosagens diferentes de ximelagatrano (24 mg and 36 mg, duas vezes ao dia). O tratamento com ximelagatrano mostrou freqüência significantemente menor de TEV que o tratamento com varfarina, mas somente na dosagem de 36-mg [risco relativo, RR 0.72 ([intervalo de confiança, IC, 95% 0.64, 0.81), p < 0.00001]. A freqüência de TEV no sub-grupo de 24-mg foi similar a da varfarina [RR 0.86 (IC 95% 0.73, 1.01), p = 0.06]. Para TEV maior, embolia pulmonar, sangramento e sangramento maior não houve diferença entre varfarina e a ximelagatrano. Ao final do tratamento, a elevação da alanino-aminotransferase (ALT) foi menos freqüente no sub-grupo de 24 mg de ximelagatrano que no grupo da varfarina [RR 0.33 (IC 95% 0.12, 0.91) p = 0.03], mas no período de acompanhamento essa elevação foi maior com 36 mg de ximelagatrano [RR 6.97 (IC 95% 1.26, 38.50) p = 0.03]. CONCLUSÃO: O ximelagatrano foi mais efetivo que a varfarina quando usado em dosagens maiores (36 mg, 2 vezes ao dia), mas às expensas de aumento de enzimas hepáticas no período de acompanhamento.
Downloads
Referências
Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. J Vasc Br. 2002;1(2):133-70. Available from: http://www.jvascbr.com.br/02-01-02/02-01-02-133/02-01-02- 133.pdf. Accessed in 2006 (Out 18).
Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Anti- thrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):338S-400S.
Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996;347(9002):635-9.
Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am. 1997;79(3):326-33.
Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replace- ment. N Engl J Med. 1997;337(19):1329-35.
Gustafsson D, Elg M. The pharmacodynamics and pharmaco- kinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. 2003;109(Suppl 1):S9-15.
Eriksson BI. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thromb Res. 2003;109(Suppl 1):S23-9.
Zufferey P, Laporte S, Molliex S, Auboyer C, Mismetti P. Ximelagatran and melagatran vs. low-molecular-weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration. J Thromb Haemost. 2005;3(5):1104-7.
Cohen AT, Hirst C, Sherrill B, Holmes P, Fidan D. Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery. Br J Surg. 2005;92(11):1335-44.
Alderson P, Green S. Huggins JPT. Cochrane Reviewers’ Hand- book 4.2.2. Assessment of study quality. Section 4. In: Alderson P, Green S. Huggins JPT, editors. The Cochrane Library [updated December 2003]. Chichester: John Wiley & Ltd.; 2004.
Juni P, Witschi A, Bloch R, Egger M. The hazards of scor- ing the quality of clinical trials for meta-analysis. JAMA. 1999;282(11):1054-60.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003;349(18):1703-12.
Colwell CW Jr., Berkowitz SD, Lieberman JR, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005;87(10):2169-77.
Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med. 2002;137(8):648-55.
Van Aken H, Bode C, Darius H, et al. Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001;7(3):195-204.
Hirsh J, O’Donnell M, Weitz JI. New anticoagulants. Blood. 2005;105(2):453-63.
Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty. 2001;16(3):293-300.
Heit JA. Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement. Thromb Res. 2001;101(1):V163-73.
Eriksson BI, Arfwidsson AC, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replace- ment: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost. 2002;87(2):231-7.
Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the ME- THRO II randomised trial. Lancet. 2002;360(9344):1441-7.
Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibi- tor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost. 2003;89(2):288-96.
Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost. 2003;1(12):2490-6.
Colwell CW Jr., Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxa- parin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003;1(10):2119-30.
Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrilla- tion: a randomized trial. JAMA. 2005;293(6):690-8.
Olsson SB; Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362(9397):1691-8.
Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H; THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349(18):1713-21.
Sander GE, Giles TD. Ximelagatran: light at the end of the tunnel or the next tunnel? Am J Geriatr Cardiol. 2004;13(4):221-4.
Gulseth MP. Ximelagatran: an orally active direct thrombin inhibitor. Am J Health Syst Pharm. 2005;62(14):1451-67.
Turpie AG, Bauer KA, Eriksson BI, Lassen MR; PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous throm- boembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359(9319):1721-6.
Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA. Short-duration prophylaxis against venous thromboem- bolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med. 2002;162(13):1465-71.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
